Compare Stocks: BBIO, ARGX, RVMD, and NTRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$875.30 +0.8%	$877.81	$631.47 ▼ $953.58	$54.76B	0.46	349,643 shs	227,042 shs
BBIO BridgeBio Pharma	$82.80 +1.0%	$75.03	$44.10 ▼ $93.42	$16.19B	0.96	3.01 million shs	1.19 million shs
NTRA Natera	$265.38 -3.4%	$251.03	$136.21 ▼ $288.04	$38.01B	1.51	1.35 million shs	1.58 million shs
RVMD Revolution Medicines	$197.81 +0.3%	$174.85	$34.00 ▼ $203.00	$42.05B	1.39	3.14 million shs	1.74 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+2.78%	-1.66%	-5.33%	+10.24%	+28.60%
BBIO BridgeBio Pharma	-0.10%	-1.86%	+5.45%	+21.56%	+66.61%
NTRA Natera	-0.22%	+8.18%	-3.25%	+24.91%	+95.96%
RVMD Revolution Medicines	+1.98%	+9.05%	+3.85%	+38.45%	+413.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$875.30 +0.8%	$877.81	$631.47 ▼ $953.58	$54.76B	0.46	349,643 shs	227,042 shs
BBIO BridgeBio Pharma	$82.80 +1.0%	$75.03	$44.10 ▼ $93.42	$16.19B	0.96	3.01 million shs	1.19 million shs
NTRA Natera	$265.38 -3.4%	$251.03	$136.21 ▼ $288.04	$38.01B	1.51	1.35 million shs	1.58 million shs
RVMD Revolution Medicines	$197.81 +0.3%	$174.85	$34.00 ▼ $203.00	$42.05B	1.39	3.14 million shs	1.74 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+2.78%	-1.66%	-5.33%	+10.24%	+28.60%
BBIO BridgeBio Pharma	-0.10%	-1.86%	+5.45%	+21.56%	+66.61%
NTRA Natera	-0.22%	+8.18%	-3.25%	+24.91%	+95.96%
RVMD Revolution Medicines	+1.98%	+9.05%	+3.85%	+38.45%	+413.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,056.89	20.75% Upside
BBIO BridgeBio Pharma	2.82	Moderate Buy	$97.33	17.55% Upside
NTRA Natera	2.82	Moderate Buy	$267.83	0.92% Upside
RVMD Revolution Medicines	2.95	Moderate Buy	$153.05	-22.63% Downside

Current Analyst Ratings Breakdown

Latest BBIO, ARGX, RVMD, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	RVMD Revolution Medicines	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$230.00
8/6/2026	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$192.10 ➝ $201.00
8/6/2026	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$230.00
8/6/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$182.00 ➝ $203.00
8/6/2026	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$235.00 ➝ $240.00
8/6/2026	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$236.00 ➝ $240.00
8/4/2026	ARGX argenex	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1,185.00
7/28/2026	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$1,000.00 ➝ $1,050.00
7/27/2026	ARGX argenex	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$867.00 ➝ $932.00
7/24/2026	ARGX argenex	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$1,014.00 ➝ $1,037.00
7/24/2026	ARGX argenex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$945.00 ➝ $1,025.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	12.89	$22.11 per share	39.59	$134.54 per share	6.51
BBIO BridgeBio Pharma	$579.96M	27.91	N/A	N/A	($10.77) per share	-7.69
NTRA Natera	$2.31B	16.48	N/A	N/A	$12.38 per share	21.44
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	$8.44 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	33.61	24.47	1.07	32.19%	43.59%	36.66%	N/A
BBIO BridgeBio Pharma	-$724.93M	-$3.74	N/A	1,182.86	N/A	-124.42%	N/A	-65.81%	8/10/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.63	N/A	N/A	N/A	-9.05%	-14.74%	-10.27%	8/6/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$7.07	N/A	N/A	N/A	N/A	-83.22%	-59.06%	N/A

Latest BBIO, ARGX, RVMD, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	N/A	N/A	N/A	$220.91 million	N/A
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion
5/7/2026	Q1 2026	BBIO BridgeBio Pharma	-$0.70	-$0.84	-$0.14	-$0.84	$178.07 million	$194.52 million
5/6/2026	Q1 2026	RVMD Revolution Medicines	-$1.83	-$2.29	-$0.46	-$2.29	$2.43 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
BBIO BridgeBio Pharma	N/A	1.52	1.48
NTRA Natera	N/A	2.96	2.83
RVMD Revolution Medicines	0.19	6.80	6.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BBIO BridgeBio Pharma	99.85%
NTRA Natera	99.90%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BBIO BridgeBio Pharma	14.23%
NTRA Natera	5.05%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
BBIO BridgeBio Pharma	400	195.49 million	167.67 million	Optionable
NTRA Natera	6,140	143.21 million	135.98 million	Optionable
RVMD Revolution Medicines	250	212.60 million	196.44 million	Optionable

BBIO, ARGX, RVMD, and NTRA Headlines

Recent News About These Companies

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

2 hours ago | zacks.com

Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00

August 6 at 8:05 AM | marketbeat.com

Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

August 6 at 4:40 AM | marketbeat.com

Revolution Medicines Q2 Earnings Call Highlights

August 5 at 12:02 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results

August 5 at 11:40 PM | marketbeat.com

Revolution Medicines Q2 Net Loss Widens

August 5 at 10:24 PM | finance.yahoo.com

Revolution Medicines updates 2026 GAAP operating expenses to $2.1B-$2.2B while preparing potential daraxonrasib launch

August 5 at 10:24 PM | seekingalpha.com

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

August 5 at 4:02 PM | globenewswire.com

Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year High - Time to Buy?

August 5 at 11:59 AM | marketbeat.com

Amundi Buys 118,493 Shares of Revolution Medicines, Inc. $RVMD

August 5 at 3:03 AM | marketbeat.com

Royal Bank of Canada Sells 131,978 Shares of Revolution Medicines, Inc. $RVMD

August 4 at 4:56 AM | marketbeat.com

The Manufacturers Life Insurance Company Decreases Position in Revolution Medicines, Inc. $RVMD

August 3 at 5:11 AM | marketbeat.com

Revolution Medicines, Inc. $RVMD Shares Sold by Defilade Capital Management L.P.

August 3 at 4:23 AM | marketbeat.com

First Trust Advisors LP Boosts Holdings in Revolution Medicines, Inc. $RVMD

August 3 at 3:35 AM | marketbeat.com

California State Teachers Retirement System Boosts Stock Position in Revolution Medicines, Inc. $RVMD

August 3 at 3:27 AM | marketbeat.com

Seven Fleet Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

August 2, 2026 | marketbeat.com

Perceptive Advisors LLC Purchases New Position in Revolution Medicines, Inc. $RVMD

August 2, 2026 | marketbeat.com

15,000 Shares in Revolution Medicines, Inc. $RVMD Bought by Avidity Partners Management LP

August 1, 2026 | marketbeat.com

Edgestream Partners L.P. Invests $6.74 Million in Revolution Medicines, Inc. $RVMD

July 31, 2026 | marketbeat.com

Dimensional Fund Advisors LP Sells 317,032 Shares of Revolution Medicines, Inc. $RVMD

July 31, 2026 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by Brokerages

July 31, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BBIO, ARGX, RVMD, and NTRA Company Descriptions

argenex NASDAQ:ARGX

$875.30 +7.36 (+0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$874.93 -0.37 (-0.04%)

As of 05:03 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BridgeBio Pharma NASDAQ:BBIO

$82.80 +0.81 (+0.99%)

Closing price 04:00 PM Eastern

Extended Trading

$82.82 +0.02 (+0.02%)

As of 04:55 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Natera NASDAQ:NTRA

$265.38 -9.24 (-3.36%)

Closing price 04:00 PM Eastern

Extended Trading

$308.14 +42.76 (+16.11%)

As of 05:06 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines NASDAQ:RVMD

$197.81 +0.51 (+0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$199.45 +1.64 (+0.83%)

As of 05:05 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBIO, ARGX, RVMD, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBIO, ARGX, RVMD, and NTRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBIO, ARGX, RVMD, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BBIO, ARGX, RVMD, and NTRA Company Descriptions

argenex NASDAQ:ARGX

BridgeBio Pharma NASDAQ:BBIO

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBIO, ARGX, RVMD, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBIO, ARGX, RVMD, and NTRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBIO, ARGX, RVMD, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BBIO, ARGX, RVMD, and NTRA Company Descriptions

argenex NASDAQ:ARGX

BridgeBio Pharma NASDAQ:BBIO

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools